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Abstract 
Objectives. The aim of this study was to compare liver-related mortality and liver-related hospitalizations for 
persons living with HIV (PLWH) with and without hepatitis C virus (HCV) exposure, and to estimate the 
fraction of liver disease attributable to chronic HCV coinfection. 
Methods. An ambispective cohort study followed PLWH between 1993 and 2014. PLWH were classified into 
three groups: those who were HIV-monoinfected, those who cleared HCV spontaneously and those with chronic 
HCV coinfection. Liver-related mortality was estimated for the three groups and compared with the adjusted 
standardized mortality ratio. 
Results. Data for 2379 PLWH were included in the study (1390 monoinfected individuals, 146 spontaneous 
HCV resolvers and 843 with chronic HCV coinfection). Global mortality was 33.8%, 21.4% of which was liver-
related. Patients who died from liver-related causes were mostly on antiretroviral therapy and had an 
undetectable HIV viral load when they died. The liver-related mortality rate in those with chronic HCV 
coinfection was 10.01 per 1000 patient-years vs. 3.84 per 1000 patient-years in the HIV-monoinfected group (P 
< 0.001). The adjusted standardized mortality ratio in the chronically HCV-coinfected group was 4.52 (95% 
confidence interval 2.98–5.86). The fractions of liver-related mortality and liver-related hospitalizations 
attributable to chronic HCV coinfection were 0.61 and 0.74, respectively. There were no differences in liver-
related events between HIV-monoinfected individuals and those who spontaneously cleared HCV. 
Conclusions. Chronic HCV infection increases the risk of liver-related mortality and liver-related 
hospitalizations in PLWH, despite good control of HIV infection. Sixty per cent of liver-related mortality in 
chronically HCV-coinfected PLWH could be attributable to chronic HCV infection. The effect of mass HCV 
eradication with new therapies should be evaluated. 
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Introduction 
Liver disease is an important contributor to morbidity and mortality among persons living with 
HIV (PLWH). Liver-related mortality is common in PLWH with chronic hepatitis C virus (HCV) 
coinfection, accounting for 20–40% of all deaths, and is the main cause of liver-related 
hospitalizations [1, 2]. 
 
In chronically HCV-infected persons without HIV infection, approximately 55–65% of liver-
related mortality can be attributed to chronic HCV infection, when compared with persons who 
spontaneously clear HCV. In many cases, HCV infection is associated with a particular lifestyle 
profile and, in the general population, spontaneous HCV resolvers are a good benchmark group 
comparator for evaluation of the independent contribution of chronic HCV infection, because they 
have the same risk factors and lifestyle as those with chronic HCV infection [3]. In PLWH, the 
differences between HIV-monoinfected individuals and spontaneous HCV resolvers in terms of liver-
related mortality and liver-related hospitalizations are unknown. 
 
The role of hepatitis viruses in the progression of liver damage is unquestionable. However, there 
are many other factors that contribute to the development of liver injury in PLWH, such as HIV 
replication, immune dysfunction, opportunistic infections, lifestyle exposures (alcohol or other 
drugs), metabolic disorders and some antiretroviral agents [4-7]. Sometimes these other factors can 
be overlooked because of the major role of HCV infection in the progression of liver disease in 
chronically HCV-coinfected PLWH. The aim of this study was to compare liver-related mortality and 
liver-related hospitalizations in PLWH with and without HCV exposure and to estimate the fraction 
of liver disease attributable to chronic HCV coinfection in this population. 
Methods 
This study included data for all PLWH followed in an ambispective cohort in a reference HIV 
clinic (University Hospital of A Coruña, Spain) between 1993 and 2014. All hospital admissions and 
the causes of death were obtained from the hospital records encoded according to the International 
Classification of Diseases (ICD-9). Liver-related disease was considered to include the following 
codes: viral hepatitis (070, 573.3), alcoholic liver disease (571.0−571.3), nonalcoholic liver disease 
(570, 571.4−571.9, 572−573), primary liver cancer (155), and decompensated cirrhosis (789.5, 
567.23, 456.0). Cholelithiasis and cholecystitis (574−575) were not included as liver-related 
conditions. Fatal infections occurring in PLWH with cirrhosis were classified as liver-related 
deaths/hospitalizations when the episode included a code for cirrhotic decompensation. 
 
Clinical and epidemiological variables were collected and a descriptive analysis was performed 
for all the variables recorded. PLWH were classified into three groups: those without viral hepatitis 
[negative for hepatitis B virus (HBV) surface antigen and HCV antibodies], those who spontaneously 
cleared HCV (HCV antibody-positive and undetectable HCV RNA without anti-HCV therapy) and 
chronically HCV-coinfected patients. PLWH who received anti-HCV therapy and achieved a 
sustained viral response (SVR) were excluded; those without an SVR were included in the 
chronically HCV-coinfected group. 
 
Quantitative variables were reported as mean ± standard deviation (SD) and qualitative variables 
as frequency and percentage. The three groups were compared using chi-square for qualitative 
variables and one-way analysis of variance (anova) for quantitative variables. 
The liver-related mortality rate was estimated in the three groups (monoinfected individuals, HCV 
spontaneous resolvers and chronically HCV-coinfected individuals). Liver-related mortality rates 
were compared using the monoinfected group as the reference, and computing the standardized 
mortality ratios with their 95% confidence intervals (CIs), adjusted for sex, age at HIV diagnosis and 
transmission route, using Byar's approximation of the Poisson model. Liver-related hospitalization 
rates were calculated and compared between groups using the adjusted standardized hospitalization 
ratios. 
  
The fraction of liver-related mortality attributable to chronic HCV infection was calculated 
relative to that in monoinfected PLWH using the equation (liver-related mortality rate in chronically 
HCV-coinfected group – liver-related mortality rate in monoinfected group)/liver-related mortality 
rate in chronically HCV-coinfected group, and relative to that in spontaneous resolvers as (liver-
related mortality rate in chronically HCV-coinfected group – liver-related mortality rate in 
spontaneous resolvers)/liver-related mortality rate in chronically HCV-coinfected group [3]. The 
fraction of liver-related hospitalizations attributable to chronic HCV infection was calculated in a 
similar fashion. Results are expressed with the 95% CI. 
 
Statistical analysis was performed using spss for Windows (v19.0; IBM Corp., Armonk, NY, 
USA). The research protocol was approved by the Regional Ethics Committee (register code 
2015/164). 
Results 
A total of 2379 PLWH followed between 1993 and 2014 were included in the study, contributing 
26 778 patient-years. The cohort included 75.2% men and had a mean (±SD) of 11.9 ± 4.2 years of 
follow-up. The main characteristics of the three study groups are shown in Table 1. The prevalence of 
HBV coinfection in chronically HCV-coinfected PLWH was 10.1%. Sixty-four (7.6%) of the 843 
chronically HCV-coinfected PLWH had been treated with anti-HCV agents, all of which were 
interferon (IFN)-based regiments, without achieving SVR. Seventy chronically HCV-coinfected 
PLWH who were successfully treated with anti-HCV therapy were excluded. The mean (±SD) 
duration of HCV infection in the chronically HCV-coinfected group was 13.4 ± 4.2 years. 
  
Table 1. Demographic characteristics, hospitalizations and mortality rates among monoinfected people living with HIV 
(PLWH), PLWH with spontaneous hepatitis C virus (HCV) clearance and PLWH with chronic HCV coinfection 
 
Monoinfected 
PLWH 
PLWH who were 
spontaneous resolvers 
Chronically HCV-
coinfected PLWH 
P-value 
     
Number of patients 1390 146 843   
Male (%) 77.99 69.86 71.65 0.065 
Age at HIV diagnosis (years) 
[mean ± SD] 
34.8 ± 9.6 29.8 ± 10.2 28.4 ± 7.4 0.002 
HIV transmission route (%)       < 0.001 
IDU 23.96 81.51 83.99   
MSM 42.01 8.90 10.32   
CD4 count nadir (cells/μL) [mean 
± SD] 
204 ± 102 184 ± 126 163 ± 108 < 0.001 
CDC-C (%) 51.9 54.8 59.4 0.002 
Total follow-up (patient-years) 13 920 1766 11 092 < 0.001 
Liver-related mortality events [n 
(%)] 
54 (3.88) 7 (4.79) 111 (13.17) < 0.001 
Non-liver-related mortality events 
[n (%)] 
388 (27.91) 40 (27.40) 203 (24.08) 0.134 
Liver-related mortality rate (95% 
CI)a 
3.88 (2.99–5.03) 3.96 (1.92–8.16) 10.01 (8.31–12.04) < 0.001 
Non-liver-related mortality rate 
(95% CI)a 
27.87 (25.27–30.74) 22.65 (16.68–30.69) 18.30 (15.97–20.97) 0.140 
Liver-related hospitalizations (n) 105 15 326 – 
Non-liver-related hospitalizations 
(n) 
3329 376 2578 – 
Liver-related hospitalization rate 
(95% CI)a 
7.54 (6.23–9.12) 8.49 (5.15–13.97) 29.39 (26.41–32.70) < 0.001 
Non-liver-related hospitalization 
rate (95% CI)a 
239.15 (232.14–
246.31) 
212.91 (194.45–232.62) 232.42 (224.65–240.37) 0.070 
     
 
CDC-C, Centers for Disease Control and Prevention category C; CI, confidence interval; IDU, injecting drug use; MSM, men 
who have sex with men; SD, standard deviation. 
a Per 1000 patient-years. 
In the whole cohort of PLWH, all-cause mortality involved 803 individuals (33.8%), including 
442 (31.8%) monoinfected individuals, 47 (32.2%) spontaneous HCV resolvers and 314 (37.2%) 
chronically HCV-coinfected patients. Of these, 78.6% of deaths were secondary to non-liver-related 
causes; the most common cause of death was AIDS-related (47.7% in the monoinfected group, 48.9% 
in spontaneous HCV resolvers and 48.1% in the chronically HCV-coinfected group; P = 0.106), 
followed by non-AIDS-related infections (22.8% in the monoinfected group, 19.1% in the 
spontaneous HCV resolvers and 22.6% in the chronically HCV-coinfected group; P = 0.060). The 
main causes of liver-related mortality in the chronically HCV-coinfected group were liver cancer 
(34.2%), cirrhotic decompensation (28.8%), nonalcoholic liver disease (18.9%) and alcoholic liver 
disease (10.8%), whereas in the monoinfected group, they were nonalcoholic liver disease (53.7%), 
alcoholic liver disease (27.7%), cirrhotic decompensation (11.1%) and liver cancer (5.5%). 
 
The liver mortality rate in each group is shown in Table 1. Compared with the monoinfected 
group, spontaneous resolvers had similar all-cause mortality (standardized mortality ratio 1.02; 95% 
Cl: 0.71–1.47), but mortality was higher in the chronically HCV-coinfected group (standardized 
mortality ratio 1.27; 95% CI: 1.06–1.52). The standardized liver-related mortality ratios are presented 
in Figure 1. 
  
 
 
 
Figure 1. Standardized liver-related mortality ratios and standardized liver-related 
hospitalization ratios, with monoinfected people living wih HIV (PLWH) as the 
reference. The ratios have been adjusted by gender, age at HIV diagnosis and 
transmission route, and are shown with their 95% confidence intervals. HCV, 
hepatitis C virus. 
The mean (±SD) time from HIV diagnosis to non-liver-related death was 8.1 ± 6.4 years in the 
monoinfected group, 7.6 ± 6.0 in the spontaneous HCV resolvers and 7.9 ± 6.6 in the chronically 
HCV-coinfected group (P = 0.062). In contrast, the mean (±SD) time from HIV diagnosis to liver-
related death was 7.6 ± 6.8 years in the monoinfected group, 7.9 ± 6.1 in the spontaneous HCV 
resolvers and 13.3 ± 7.1 in the chronically HCV-coinfected group (P = 0.003). Those PLWH who 
died of liver-related causes were mostly undergoing antiretroviral treatment when they died (87.0% 
of the monoinfected group, 85.7% of the spontaneous HCV resolvers and 90.0% of the chronically 
HCV-coinfected group; P = 0.810), and most had controlled HIV replication (< 400 HIV-1 RNA 
copies/mL) (74.0% of the monoinfected group, 71.0% of the spontaneous HCV resolvers and 76.6% 
of the chronically HCV-coinfected PLWH). 
 
During the study period, 6729 hospitalizations were recorded (6.6% liver-related) in 1844 patients 
(77.5% of the whole cohort); the median number of admissions was 2 (range 1–4). The main reasons 
for hospitalization of monoinfected PLWH were AIDS-related diseases (26.2%), other infections 
(28.5%) and cardiovascular disease (14.3%) whereas in the chronically HCV-coinfected group they 
were AIDS-related diseases (24.8%), other infections (27.7%) and liver-related diseases (11.2%). 
Figure 1 shows the standardized liver-related hospitalization ratios. 
 
There were no differences in liver-related hospitalizations and liver-related mortality between 
monoinfected PLWH and PLWH who spontaneously cleared HCV. After adjusting for age at HIV 
diagnosis, sex and transmission route, chronically HCV-coinfected individuals showed a more than 
fourfold higher rate of liver-related mortality and close to a sevenfold higher rate of liver-related 
hospitalizations than monoinfected PLWH (P < 0.001), as shown in Figure 1. 
 
The fraction of liver-related mortality attributable to chronic HCV infection in PLWH relative to 
monoinfected PLWH was 0.61 (95% CI: 0.51–0.70) and that relative to spontaneous resolvers was 
0.60 (95% CI: 0.51–0.69). The fraction of liver-related hospitalizations in chronically HCV-
coinfected PLWH vs. monoinfected PLWH was 0.74 (95% CI: 0.69–0.79) and that vs. spontaneous 
resolvers was 0.71 (95% CI: 0.66–0.76); these were not significantly different (P = 0.102). 
  
Discussion 
In this study, more than one-third of deaths and 11% of hospitalizations in chronically HCV-
coinfected PLWH were liver-related, as previously documented [8]. After adjustment, chronically 
HCV-coinfected PLWH had a higher mortality than monoinfected PLWH, mainly bacause of liver-
related causes (standardized mortality ratio 6.92). There were no differences in terms of liver events 
between monoinfected PLWH and those who spontaneously resolved HCV infection. This similarity 
may be partly explained by their similar lifestyle exposures, despite the lower proportion of injecting 
drug users in monoinfected PLWH than in spontaneous resolvers and the higher prevalence of other 
liver and metabolic disorders (such as steatosis) in PLWH, compared with the general population [4]. 
Therefore, in this population, patients without viral hepatitis could be used as a benchmark group 
comparator to explore the relative contribution of chronic HCV infection. 
 
To our knowledge, this is the first study estimating the fraction of liver disease in PLWH 
attributable to chronic HCV infection. These data agree with the opinion that the majority of liver 
deaths in chronically HCV-coinfected patients are attributable to chronic HCV exposure. The 
attributable-fraction analysis provides further information: it shows that a significant proportion of 
liver-related mortality can occur independently of HCV infection, which should be considered when 
the future impact of treatment for HCV infection is estimated [1, 2]. There are several studies 
evaluating the role of SVR to HCV treatment in liver disease progression and liver-related mortality 
in PLWH, most of which were included in a recent meta-analysis [9]. However, these studies were 
performed during the IFN era when less than one-third of patients elected to have anti-HCV therapy, 
so the favourable impact of HCV eradication could be maximized, due to selection bias [10]. Survival 
of PLWH achieving SVR in these classical studies was usually better than that of HCV-uninfected 
PLWH because of a selection bias. Consequently, more data on treatment and survival with the newer 
anti-HCV treatments and a more diverse sample population are needed [1]. 
 
In case−control studies comparing chronically HCV-infected patients with and without HIV 
infection, effective HIV control reduced, but did not eliminate, the higher risk of liver disease 
progression in coinfected patients in terms of hepatic decompensation, fibrosis progression and 
hepatocellular carcinoma, and was inversely related to the CD4 count [11, 12]. Our study did not 
include data on the CD4 count at the time of the liver events, but chronically HCV-coinfected PLWH 
had a lower CD4 nadir than did monoinfected PLWH, despite similar antiretroviral treatment 
exposure and efficacy in terms of HIV viral load suppression. 
 
This study has some limitations. First, some deaths (such as those attributable to infections in 
cirrhotic patients, or cancers other than hepatocellular carcinoma in which chronic HCV infection 
was involved) were coded as non-liver-related disease despite the important contribution of chronic 
HCV infection. Secondly, some important variables such as alcohol intake and active drug use were 
not available. Thirdly, PLWH with hepatitis B or D were excluded unless they were chronically 
HCV-coinfected, and the effect of these hepatitis coinfections on liver-related events was not 
considered. The impact of anti-HCV treatment and achievement of an SVR were not evaluated. 
Finally, the immunological status of PLWH was not appropriately recorded. 
 
In conclusion, similar to the general population, close to two-thirds of liver-related mortality in 
chronically HCV-coinfected PLWH could be attributed to chronic HCV infection, but the liver-
related mortality rate in PLWH was double that found in the general population (10.01 vs. 5.35 per 
1000 patient-years, respectively) [3]. Chronic HCV infection is a relevant problem in PLWH, 
significantly increasing the rates of morbidity and mortality. Eradication of chronic HCV coinfection 
is crucial in PLWH, but is probably not a definitive solution to the problem of liver disease, and 
preventive, educational and social interventions are particularly important in PLWH. 
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